Biomarin Pharmaceutical Inc (BMRN.OQ)
23 Jul 2019
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|65||2015||Chairman of the Board, Chief Executive Officer|
|59||2012||Chief Financial Officer, Executive Vice President|
|61||2016||President - Worldwide Research & Development|
|47||2016||Executive Vice President, General Counsel, Secretary|
|56||2013||Executive Vice President, Chief Commercial Officer|
- UPDATE 3-BioMarin says data shows hemophilia gene therapy effects could wane
- BRIEF-BioMarin Says Payers Unlikely To Accept Price Equivalent To Over 5 Years Of Standard Treatment Costs For Hemophilia Gene Therapy
- BioMarin says hemophilia gene therapy meets certain criteria in late-stage trial
- UPDATE 3-Roche 'steps up' for gene therapy with $4.3 bln Spark bet
- Catalyst Pharma sees net price of drug, once free, topping $300,000